

Comparison of Macrodosimetric Efficacy of Transarterial Radioembolization (TARE) by Using ⁹⁰Y Microspheres of Different Density of Activity

Traino AC^{1*}, Piccinno M¹, Boni G², Bargellini I³ and Bozzi E³

¹Unit of Medical Physics, University Hospital Pisana, Italy

²Unit of Nuclear Medicine, University Hospital Pisana, Italy

³S.D Radiologia Vascolare and Interventional, University Hospital Pisana, Italy

Abstract

Purpose: Transarterial ⁹⁰Y microspheres radioembolization is emerging as a multidisciplinary promising therapeutic modality for primary and metastatic cancer in the liver. Actually two different type of microspheres are used, whose main characteristic is the different density of activity (activity per microsphere). In this paper the effect due to the possible different distribution of the microspheres in a target is presented and discussed from a macrodosimetric point of view.

Material and methods: A 100 g virtual soft-tissue target region has been builded. The administered activity was chosen to have a target average absorbed dose of 100 Gy and the number of ⁹⁰Y microspheres needed was calculated for two different activity-per-microsphere values (2500 Bq/microsphere and 50 Bq/microsphere, respectively). The spheres were randomly distributed in the target and the Dose Volume Histograms were obtained for both. The cells surviving fractions (SF) for four different values of the radiobiological parameter α were calculated from the Linear - Quadratic model.

Results: The DVH obtained are very similar and the SF is almost equal for both the activity-per- microsphere values.

Conclusions: This macrodosimetric approach shows no radiobiological difference between the glass and resin microspheres. Thus the different number of microspheres seems to have no effect when the number of spheres is big enough that the distance between the spheres in the target can be considered small compared to the range of the β -particles of ⁹⁰Y.

Keywords: Microspheres; β -particles; Linear-quadratic model; TheraSphere

Introduction

Radioembolization with ⁹⁰Y microspheres via hepatic arterial administration has been shown to be effective in the treatment of primary and metastatic liver cancer (HCC), as well as in unresectable colon carcinoma metastases [1-5]. Radioembolization is a loco-regional liver directed therapy that involves transcatheter delivery of microspheres embedded with ⁹⁰Y. ⁹⁰Y microspheres are injected into the arterial supply of the liver, where they preferentially flow into hyper vascularized tumor zones, with a higher irradiation of tumour tissue compared to the normal liver parenchyma, with a consequent tumour-tissue necrosis. Actually ⁹⁰Y can be delivered to the hepatic tumor as either a constituent of a glass microsphere, TheraSphere[®], or as a biocompatible resin-based microsphere, SIR-Spheres[®]. TheraSphere[®] was approved by the USA Food and Drug Administration for unresectable HCC in December 1999 under a Humanitarian Device Exemption. SIR-Spheres[®] was approved in March 2002 for colorectal cancer metastatic to the liver in conjunction with continuous infusion of intrahepatic floxuridine (FUDR) [6].

The characteristics of these two different kinds of ⁹⁰Y microspheres are summarized in Table 1 [7]. From a dosimetric point of view, the main difference between SIR-Spheres[®] and TheraSphere[®] is the density of activity that in one case (SIR-Spheres[®] whose activity per microsphere is ~50 Bq) is much lower than in the other (TheraSphere[®] whose activity per microsphere is 2500 Bq).

In principle this difference could have an impact on the

radiobiological effectiveness of the treatment [8], due to the much higher number of microspheres needed to have the same activity in the target tissue in one case (SIR-Spheres[®]) compared to the other (TheraSphere[®]). This because an higher number of microspheres could mean a more homogeneous distribution of activity (and consequently of target absorbed dose).

⁹⁰ Y-Microspheres		
Material	Resin	Glass
Sphere size (mm)	20-60	20-30
Activity per sphere (Bq)	40-70	2500
Specific gravity	Low	High
Handling for dispensing	Required	Not required
Splitting one vial for more patients	Possible	Not possible

Table 1: Main characteristics of the two available kinds of ⁹⁰Y microsphere: Glass spheres (TheraSphere[®]) and resin spheres (SIR-Spheres[®]).

***Corresponding author:** Traino AC, Professor, Unit of Medical Physics, University Hospital Pisana, Italy, Tel: +39 050992957; E-mail: c.traino@ao-pisa.toscana.it

Received July 01, 2015; **Accepted** January 11, 2016; **Published** January 15, 2016

Citation: Traino AC, Piccinno M, Boni G, Bargellini I, Bozzi E (2016) Comparison of Macrodosimetric Efficacy of Transarterial Radioembolization (TARE) by Using ⁹⁰Y Microspheres of Different Density of Activity. J Phys Math 7: 150. doi:10.4172/2090-0902.1000150

Copyright: © 2016 Traino AC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

In this paper a comparison of these two different densities of activity is presented and discussed, showing that, neglecting other differences between the two types of 90Y microspheres (different material and consequent different specific gravity of SIR-Spheres® compared to TheraSphere®, for example) the therapeutic effectiveness of the two radioembolization tools is almost the same from a macrodosimetric point of view.

Materials and Methods

A cubical target was simulated to test the expected difference between the two different activities-per-sphere tools. The mass of the target was 100 g, its density was 1.04 g/cm³, that is the density of the soft tissues [9]. The activity needed for an average target absorbed dose of 100 Gy was calculated by using the MIRD formalism:

$$D(r_T, \infty) = S(r_T \leftarrow r_T) \int_0^{\infty} A_0 e^{-\lambda t} dt = S(r_T \leftarrow r_T) \frac{A_0}{\lambda}$$

where $D(r_T, \infty) = 100$ Gy is the target absorbed dose; $S(r_T, r_T) = 5.08$ mGy/MBq*h is the S-value for a self-irradiating 100 g spherical target treated with 90Y; A_0 = administered activity and $\lambda = 0.011$ h⁻¹ is the physical decay constant of 90Y. From Equation 1 it follows $A_0 = 213$ MBq.

The target volume was divided into $N = 21 \times 21 \times 21$ square voxels of 2.21 mm size.

A number n_{sph} of 90Y embedded microspheres of the same size were randomly distributed into the target, according with the equation:

$$n_{sph} = \frac{A_0}{\delta_a}$$

Where δ_a represents two different densities of activity of 2500 Bq/sphere and 50 Bq/sphere respectively. For an administered activity of 213 MBq there will be $n_{sph} = 8.52 \times 10^4$ 90Y microspheres corresponding to a density of activity $\delta_a = 2500$ Bq/sphere (glass spheres) and $n_{sph} = 4.26 \times 10^6$ 90Y microspheres corresponding to $\delta_a = 50$ Bq/sphere (resin spheres). The size was considered the same, 30µm, for both the type of microspheres.

Software was built by using the open-source environment GNU-Octave to randomly distribute a number n_{sph} of microspheres in the target, to perform a 3D dosimetric calculation at the voxel level by using the MIRD 17 method [10] and to show the Dose Volume Histogram (DVH) corresponding to the different distributions of the 90Y microspheres.

The absorbed dose di in each voxel was calculated, according to the MIRD 17 method, by using the equation:

$$d_i = \sum_{h=0}^n \tilde{A}_h S_{i \leftarrow h} = \sum_{h=0}^n S_{i \leftarrow h} \int_0^{\infty} A_0 e^{-\lambda t} dt$$

where \tilde{A}_h is the cumulated activity in the i th-voxel and $S_{i \leftarrow h}$ are the dose conversion factors at the voxel level. The $S_{i \leftarrow h}$ values for the voxel size of 2.21 mm were taken [9] Note that A_h is the activity in each h voxel, calculated by multiplying the number of microspheres randomly placed in that voxel by the density of activity δ_a .

Results

The Dose Volume Histograms for $\delta_a = 2500$ Bq/sphere and $\delta_a = 50$ Bq/sphere are shown in Figure 1. DVHs for the two values of δ_a considered are very similar.

The surviving fraction SF was calculated for each of the two values of δ_a by using the Linear-




Figure 1: Integral DVH in a target region of 100 g calculated for $\delta_a = 2500$ Bq/sphere and $\delta_a = 50$ Bq/sphere respectively. The administered activity $A_0 = 213$ MBq, needed to have an average absorbed dose of 100 Gy from the target region.

Surviving Fraction		
a (1/Gy)	2500 Bq/sphere	50 Bq/sphere
1	5.90E-21	4.30E-27
0.1	1.02E-04	6.00E-05
0.01	0.32	0.32
0.001	0.89	0.89

Table 2: Cells surviving fractions for different values of a and different values of δ_a (2500 Bq/sphere and 50 Bq/sphere). The calculation was based on equation 4 with $a/b = 10$ and $G = 0.023$.

Quadratic (LQ) model:

$$SF = \frac{1}{N} \sum_{i=1}^N e^{-(\alpha d_i + G\beta d_i^2)}$$

In Equation 4 $\beta = 10$ and the Lea-Catcheside factor $G = 0.023$. This last factor for a mono-exponential decreasing dose-rate can be written as [11].

$$G = \frac{\lambda}{\mu + \lambda}$$

Where $\mu = \ln(2)/t_{rep}$ is the rate of repair of sub-lethal damages (the repair half-time constant $t_{rep} = 1.5$ h for tumor lesions was extracted from Strigari [12] and $\lambda = 0.011$ h⁻¹ is the physics decay rate of 90Y. The cells surviving fraction for four different values of α ($\alpha = 1; 0.1; 0.01$ and 0.001 Gy⁻¹) is shown in Table 2.

Discussion and Conclusions

From a macrodosimetric point of view, the different number of 90Y microspheres per unit mass could have an impact on the radiobiological effect of the transarterial radioembolization therapy [8], due to the different distribution of the microspheres in the treated target region. The microspheres tend to be distributed as homogeneously as possible via the microvascularization of the target zone. The homogeneous distribution of the activity represents the better situation from a

radiobiological point of view, because it causes an uniform absorbed dose by the target. In this paper the hypothesis of a random distribution of the microspheres in the target has been done, without considering the trapping of the spheres in the blood vessels.

If the microspheres are rarefied in the target, meaning that the average distance between spheres is higher than than the double range of the β^- of the radionuclide employed (90Y in this case), the dose distribution will be very unhomogeneous, leaving target zones where the absorbed dose is zero Figure 2.

In the case described in this paper, doing the hypothesis of a random distribution of the 90Y microspheres in the target, for a 100 g target treated with an activity of 213 MBq, which corresponds to a target absorbed dose of 100 Gy, the average density of 90Y microspheres is 0.852 spheres/mm³ if $\delta_a = 2500$ Bq/sphere and 42.6 spheres/mm³ if $\delta_a = 50$ Bq/sphere. Remembering that the range of the β^- particles of 90Y is about 11 mm in the soft tissues, this means that the β^- Particles of the 90Y are close also for $\delta_a = 2500$ Bq/sphere, compared to their range. Thus for the glass microspheres ($\delta_a = 2500$ Bq/sphere) there are low high-activity spheres for unit mass, compared to an higher number of low-activity resin microspheres ($\delta_a = 50$ Bq/sphere). In both cases the effect of the microspheres is almost homogeneous in the volume considered, because the average distance among the spheres is lower than the range of the β^- particles of 90Y Figure 3.

In Table 3 the average density (number of spheres/mm³) of 90Y glass and resin microspheres ($\delta_a = 2500$ Bq/sphere and $\delta_a = 50$ Bq/sphere respectively) needed for an average target absorbed dose of 100 Gy is shown for different target mass values. The average number of spheres per mm³ of target has a very low variation depending on target mass. This means that the macrodosimetric effect of the glass and resin 90Y microspheres is almost the same in the target, because the microspheres are very close respect to the range of the β^- particles of 90Y. This seems true for all the possible treated masses, if the required target average absorbed dose is 100 Gy.

The random distribution of the microspheres in the whole target is only a hypothesis. The real situation is different because the microspheres are vehiculated into the target by the arterial system: this means that the distribution of the spheres in the target is unhomogeneous in principle. In the real situation the 90Y activity




Figure 2: Representation of a rarefied distribution of microspheres in the target. If the distance between two microspheres is bigger than the double range of the β^- particles there is a no-absorbed energy (and then no-absorbed dose) zone. This means a very unhomogeneous absorbed dose distribution in the target.




Figure 3: 2D representation of the target region, divided into cubical voxels of 2.21 mm size. The

90Y microspheres are randomly distributed in the voxels. The average number of glass microspheres per voxel is 9.2; the average number of resin microspheres per voxel is 459.8. The microspheres are closer than the β^- range of the 90Y (maximum range: 11 mm; average range: 2.5 mm)

Target Mass (g)	Administered Activity (MBq)	Average Number of Glass Spheres/mm ³	Average Number of Resin Spheres/mm ³
40	86	0.866	43.3
80	170	0.854	42.7
100	213	0.853	42.6
300	626	0.835	41.7
400	833	0.833	41.7
500	1041	0.833	41.7
100	2059	0.825	41.2
2000	4026	0.805	40.3

Table 3: Density (number of spheres/mm³) of glass and resin microspheres ($\delta_a = 2500$ Bq/sphere and $\delta_a = 50$ Bq/sphere respectively) for different masses of soft-tissue target. The administered activity corresponds to an average target absorbed dose of 100 Gy; the density of the soft-tissue is 1.04 Kg/dm³.

needed to have a certain absorbed dose (es.100 Gy) in a target volume (es. 100 g) is forced in a volume smaller than the target (arterial system in the target is smaller than the whole target). This means that there is the same number of microspheres (8.52×10^4 90Y microspheres corresponding to a density of activity $\delta_a = 2500$ Bq/sphere and 4.26×10^6 corresponding to $\delta_a = 50$ Bq/sphere) randomly distributed in a volume lower than 100 g. For this reason the 90Y microspheres are much closer than the situation described in this paper, thus the macrodosimetric differences due to the different number of resin and glass microspheres in the target are probably lower.

In this paper the macrodosimetric effect due to the different number of 90Y microspheres per unit mass in a target submitted to the radioembolization procedure is treated. From this point of view, it seems that the different number of microspheres doesn't have any effect on the distribution of the target absorbed dose due to the small distance among the spheres compared to the range of the particles of 90Y. This result seems to be in agreement with those described by Gulec in their paper [13], where, starting from a microdosimetric approach, they don't find any difference in the absorbed dose due to the different number of microspheres in the target.

The microdosimetric effects due to the different density of activity (activity per sphere) between glass and resin microspheres, already treated in literature [13,14] is beyond the scope of this paper. Also the probable radiobiological effect due to the different specific gravity of the microspheres (due to the different material), which almost surely




Figure 4: Representation of the real distribution of the 90Y microspheres in the target. The microspheres are vehiculated in the target by the arterial vascularization, thus their distribution cannot be homogeneous. The dotted lines represent the isodose curves in the target.

affects the distribution of the microspheres in the target, is not taken into consideration in this paper.

References

1. Blanchard RJ, Morrow IM, Sutherland JB (1989) Treatment of liver tumors with yttrium-90 microspheres alone. *Can Assoc Radiol J* 40: 206-210.
2. Jacobs TF (2007) Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres. *Eur Radiol* 17: 1320-1330.
3. Dancey JE (2000) Treatment of non resectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. *J Nucl Med*; 41: 1673-1681.
4. Geschwind JF (2004) Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. *Gastroenterology* 127 :S194 -S205.
5. Salem R (2005) Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. *J Vasc Interv Radiol* 16: 1627-1639.
6. Lewandowski RJ, Salem R (2006) Yttrium-90 Radioembolization of Hepatocellular Carcinoma and Metastatic Disease to the Liver. *Semin Intervent Radiol*; 23: 64-72.
7. Salem R, Thurston KG (2006) Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. *J Vasc Interv Radiol* 17: 1251-1278
8. Spreafico C, Maccauro M, Mazzaferro V, Chiesa C (2014) The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE). *Eur J Nucl Med Mol Imaging* 41: 634-638.
9. Lanconelli N (2012) A free database of radionuclide voxel S values for the dosimetry of nonuniform activity distributions. *Phys Med Biol* 57: 517-533.
10. Bolch WE (1999) the dosimetry of nonuniform activity distributions – radionuclide S values at the voxel level. *J Nucl Med* 40: 11S-36S.
11. Dale RG (1996) Dose-rate effects in targeted radiotherapy. *Phys Med Biol* 41: 1871-1884.
12. Strigari L, et al (2010) Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. *J Nucl Med* 51: 1377-1385.
13. Gulec SA, Szejnberg ML, Siegel JA, Jevremovic T, Stabin M (2010) Hepatic structural dosimetry in 90Y microspheres treatment: a Monte Carlo modeling approach based on lobular microanatomy. *J Nucl Med* 51: 301-310.
14. Walrand S, Hesse M, Chiesa C, Lhommel R, Jamar F (2014) The low hepatic toxicity per Gray of 90Y glass microspheres is linked to their transport in the arterial tree favoring a nonuniform trapping as observed in posttherapy PET imaging. *J Nucl Med* 55: 135-140.